Evidence map›Paper›PMID 38330084›Full record

ArticleBiostatistics (Oxford, England)2024

Uncertainty directed factorial clinical trials.

Gopal Kotecha, Steffen Ventz, Sandra Fortini, Lorenzo Trippa

Erratum issuedAbstract read
In one paragraph

Article in Biostatistics (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Gopal KotechaDepartment of Biostatistics, Harvard School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.ORCID 0000-0002-6768-1221
Steffen VentzDivision of Biostatistics, School of Public Health, University of Minnesota, University Office Plaza, Ste 200, 2221 University Ave SE, Minneapolis, MN 55414, USA.ORCID 0000-0003-2229-9560
Sandra FortiniDepartment of Decision Sciences, Bocconi University, Via Röntgen, 1, 20136 Milano, Italy.
Lorenzo TrippaDepartment of Biostatistics, Harvard School of Public Health, 677 Huntington Ave, Boston, MA, 02115, USA.

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Statistical Methods and Validation Analyses for the Integration of External Data in Clinical TrialsR01LM013352 · NLM · DANA-FARBER CANCER INST · PI TRIPPA, LORENZO · 2021 to 2024
$1.5M
National Cancer Institutes 5P30CA077598-23NCI NIH HHS P30 CA077598NIH HHS 1R01LM013352-01A1NLM NIH HHS R01 LM013352
6 · The paper itself

Abstract

The development and evaluation of novel treatment combinations is a key component of modern clinical research. The primary goals of factorial clinical trials of treatment combinations range from the estimation of intervention-specific effects, or the discovery of potential synergies, to the identification of combinations with the highest response probabilities. Most factorial studies use balanced or block randomization, with an equal number of patients assigned to each treatment combination, irrespective of the specific goals of the trial. Here, we introduce a class of Bayesian response-adaptive designs for factorial clinical trials with binary outcomes. The study design was developed using Bayesian decision-theoretic arguments and adapts the randomization probabilities to treatment combinations during the enrollment period based on the available data. Our approach enables the investigator to specify a utility function representative of the aims of the trial, and the Bayesian response-adaptive randomization algorithm aims to maximize this utility function. We considered several utility functions and factorial designs tailored to them. Then, we conducted a comparative simulation study to illustrate relevant differences of key operating characteristics across the resulting designs. We also investigated the asymptotic behavior of the proposed adaptive designs. We also used data summaries from three recent factorial trials in perioperative care, smoking cessation, and infectious disease prevention to define realistic simulation scenarios and illustrate advantages of the introduced trial designs compared to other study designs.

Indexed as

Bayes TheoremAlgorithmsClinical Trials as TopicHumansModels, StatisticalRandomized Controlled Trials as TopicResearch DesignUncertaintyBayesian designsFactorial designsInformation gainMulti-arm clinical trialsOptimal designsResponse-adaptive randomization

Identifiers

PMID38330084
PMCPMC11247193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.